CCA
PFE icon

Conservest Capital Advisors’s Pfizer PFE Stock Holding History

Conservest Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,815
Closed -$247K – 103
2022
Q4 		$247K Buy
+4,815
New +$231K 0.03% 76
2022
Q3 		– Sell
-5,287
Closed -$257K – 81
2022
Q2 		$277K Buy
5,287
+488
+10% +$24.9K 0.03% 76
2022
Q1 		$248K Buy
4,799
+5
+0.1% +$259 0.03% 76
2021
Q4 		$283K Buy
4,794
+4
+0.1% +$198 0.03% 77
2021
Q3 		$206K Buy
+4,790
New +$212K 0.02% 78
2018
Q1 		– Sell
-5,971
Closed -$205K – 81
2017
Q4 		$205K Buy
+5,971
New +$204K 0.04% 79

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Conservest Capital Advisors's PFE Position: Q1 2023 in Review

Conservest Capital Advisors sold out of Pfizer (PFE) in Q1 2023, closing a stake of 4,815 shares — an estimated $247K sold.

Conservest Capital Advisors first reported a position in PFE in Q4 2017 and held it in 6 quarters. The position peaked at $283K in Q4 2021. 3,103 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

  • Conservest Capital Advisors reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
  • Conservest Capital Advisors sold 4,815 Pfizer shares in Q1 2023, an estimated $247K.
  • Conservest Capital Advisors first reported a position in Pfizer in Q4 2017 and held it in 6 quarters.
  • Conservest Capital Advisors's Pfizer position peaked at $283K in Q4 2021.
  • 3,103 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Conservest Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.